Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy

2016 ◽  
Vol 17 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Yi Miao ◽  
Qin Yan ◽  
Shuangdi Li ◽  
Bilan Li ◽  
Youji Feng
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
Neutrophil To Lymphocyte Ratio ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Chemotherapeutic Response ◽  
Platinum Based Chemotherapy

scholarly journals The Impact of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Epithelial Ovarian Cancer

2021 ◽  
pp. 1-5
Author(s):  
Samet Kirat ◽  
Utku Akgor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Lymph Node Involvement ◽  
Neutrophil To Lymphocyte Ratio ◽  
Platelet To Lymphocyte Ratio ◽  
Prognostic Information ◽  
Lymphocyte Ratio ◽  
Node Involvement ◽  
The Difference ◽  
The Impact

OBJECTIVE: This study aims to investigate the prognostic value of the preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer. STUDY DESIGN: Between January 2012 and December 2018, the data and preoperative levels of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio of 116 epithelial ovarian cancer patients were retrospectively collected. The association of these relevant markers with outcomes was analyzed. RESULTS: The difference was observed concerning optimal and suboptimal debulking in platelet-to-lymphocyte ratio ratios (p=0.04). Lymphovascular space involvement was significantly associated with higher platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio ratios (p<0.0001). Patients with ascites and lymph node involvement had a higher platelet-to-lymphocyte ratio ratio (p=0.007 and p=0.004). In recurrences, higher ratios of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio were observed (p=0.03 and p=0.02). The analysis revealed that platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio were not independent prognostic factors for recurrence (p=0.783 and p=0.391). Regarding mortality, platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio were not independently prognostic (p=0.621 and p=0.830). It was determined that neutrophil-to-lymphocyte ratio >2.45 (HR 0.714, CI 0.622-0.794, p<0.0001) and platelet-to-lymphocyte ratio >179.4 (HR 0.736, CI 0.646-0.814, p<0.0001) could predict the presence of recurrence with a certain sensitivity and specificity, and for predicting the death, a neutrophil-to-lymphocyte ratio of >2.45 had a sensitivity of 78.26% (95% CI: 56.3 to 92.5%) and a specificity of 54.84% (95%CI: 44.2 - 65.2) (p=0.03). CONCLUSION: The evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is important in obtaining prognostic information before surgery. However, no significant association between the neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio with survival was identified.

The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer

2017 ◽  
Vol 66 (6) ◽  
pp. 467-475 ◽  
Author(s):  
Anastasia Prodromidou ◽  
Panagiotis Andreakos ◽  
Charalampos Kazakos ◽  
Dimitrios Eftimios Vlachos ◽  
Despina Perrea ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neutrophil To Lymphocyte Ratio ◽  
Platelet To Lymphocyte Ratio ◽  
Diagnostic Efficacy ◽  
Lymphocyte Ratio

scholarly journals Platelet-to-Lymphocyte Ratio (PLR) Profile and Neutrophil-to-Lymphocyte Ratio (NLR) in Lung Cancer Patients in Ulin General Hospital Banjarmasin 2017-2018

2020 ◽  
Vol 16 (1) ◽  
pp. 25
Author(s):  
Haryati Haryati ◽  
Holly Diany
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
General Hospital ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Stage ◽  
Platelet To Lymphocyte Ratio ◽  
Lung Cancer Patients ◽  
Lymphocyte Ratio ◽  
Anatomy Laboratory ◽  
End Stage

Abstract: Lung cancer is the leading cause of malignancy in the world reaching up to 13% of all cancer diagnoses. Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte Ratio (NLR), are promising markers of inflammatory prognosis, clinical decisions for proper management of lung cancer patients. The research used a retrospective analytic observational study as its research method. Samples were taken from Pathology Anatomy Laboratory, and the medical record data of lung cancer patients in Ulin General Hospital Banjarmasin from 2017 to 2018. Male lung cancer patients have percentage of 72% with PLR NLR values by sex are not much different p>0.05. 23% of patients were aged ≥ 65 years and 77% were aged £ 65 years with value p>0.05. Adenocarcinoma reaches 65% with p>0.05. Most metastases are 44% pleural effusion with value p>0.05. Percentage of advanced stage is 90% with a higher PLR NLR value at the end stage. There is a meaningful relationship of NLR with lung cancer stage p<0.05, but no relantionship with PLR p>0.05. PRL and NRL are increased at advanced stage. NRL and PRL did not differ significantly based on age, sex and histology of lung cancer. Keywords: Platelet-to-lympho­cyte ratio (PLR), Neutrophil-to-lymphocyte ratio (NLR), lung cancer

Sign in / Sign up

Export Citation Format

Share Document